Product
Feature
Quick Research
Generate reliable direction feasibility study reports for your R&D in just a few steps.
Technical Q&A
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
Find Solutions
As an expert in R&D theories, this can generate solutions to your technical problems instantly.
Evaluate Feasibility
Analyze your overall solution with one click, know your potential R&D risks in advance.
Monitor Landscape
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
99 results about "Gastrointestinal inflammation" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
If you have chronic inflammation of the gastrointestinal tract, you could have IBD, which primarily includes: Ulcerative colitis: Inflammation is usually on the innermost lining of your large intestine (colon). Crohn’s disease: Inflammation can occur anywhere along the lining of your digestive tract.
Cellular Constituents From Bacteroides, Compositions Thereof, and Therapeutic Methods Employing Bacteroides or Cellular Constituents Thereof
A cellular constituent is lysed from, produced by and / or isolated from one or more bacteria from the genus Bacteroides, and the cellular constituent, a derivative thereof, and / or one or more bacteria from the genus Bacteroides, or a modified form thereof, is employed in compositions and methods for modulating an inflammatory response. Such methods include methods of treating, delaying the onset of or reducing the symptoms of one or more inflammatory conditions / diseases, including corporal or gastrointestinal inflammation, for example, Irritable Bowel Syndrome, Crohn's Disease, or colitis, and / or associated diseases such diabetes, asthma, multiple sclerosis, cancer, rheumatoid arthritis, gingivitis, atopic diseases, for example, hay fever, food allergies, eczema, rhinitis, dermatitis, conjunctivitis, atopic syndrome and keratosis pelaris, ocular inflammatory disease, strokes, cardiovascular disease, depression, atherosclerosis and hypertension, and comprise administering a composition comprising one or more natural and / or modified bacteria of the genus Bacteroides, and / or a cellular constituent lysed from, produced by, or isolated from one or more natural and / or modified bacteria from the genus Bacteroides, or a derivative thereof.
Owner:MOORE RES ENTERPRISES
Orally Administered Corticosteroid Compositions
ActiveUS20110081411A1Antibacterial agentsOrganic active ingredientsGastrointestinal inflammationInflammation
The present invention is directed to orally administered corticosteroid compositions. The present invention also provides a method for treating a condition associated with inflammation of the gastrointestinal tract in an individual. The method comprises administering to an individual in need thereof a pharmaceutical composition of the present invention.
Owner:ELLODI PHARM LP
Compositions for the treatment of gastrointestinal inflammation
InactiveUS20090123390A1Treating preventing alleviating symptomSuitable for oralBiocideOrganic active ingredientsGastrointestinal inflammationDisease
Provided herein are methods for preventing or alleviating the symptoms of and inflammation associated with inflammatory diseases and conditions of the gastrointestinal tract, for example, those involving the esophagus. Also provided herein are pharmaceutical compositions useful for the methods of the present invention.
Owner:MERITAGE PHARMA INC
Methods of treatment for esophageal inflammation
Provided herein are methods for treating gastrointestinal inflammation, for example, esophageal inflammation, or reduction of eosinophilic infiltration of the esophagus and / or reducing local and systemic exposure and / or side effects resulting therefrom. Provided herein are methods for diagnosing gastrointestinal inflammation, for example, esophageal inflammation, or reduction of eosinophilic infiltration of the esophagus. Also provided herein are methods for inducing remission of eosinophilic infiltration of the esophagus
Owner:MERITAGE PHARMA INC
Cellular constituents from bacteroides, compositions thereof, and therapeutic methods employing bacteroides or cellular constituents thereof
Owner:MOORE RES ENTERPRISES
Methods of treating inflammatory conditions of the gastrointestinal tract using 4-APAA and compositions thereof
Compounds are disclosed having the structure of Formula I: where R1, R3, and R4 are independently hydrogen or C1 to C4 alkyl, and R2 is: where R5 is selected from the group consisting of hydrogen and C1 to C4 alkyl, or where R6, R7 and R8 are independently hydrogen or C1 to C4 alkyl; or the esters or pharmacologically acceptable salts thereof. Such compounds may be utilized for the prophylaxis or treatment of various diseases, particularly inflammatory conditions of the GI tract.Methods of treating inflammatory conditions of the GI tract such as inflammatory bowel disease using compounds having the following formula are also disclosed: where R9, R10 and R11 are independently selected from the group consisting of hydrogen and C1 to C4 alkyl, and R12 is selected from the group consisting of hydrogen and —C(O)R13, where R13 is a C1 to C6 alkyl or an aryl group.
Owner:BIOCON LTD
Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation
InactiveUS7485627B2Improve colitisSugar derivativesEnergy modified materialsGastrointestinal inflammationInflammatory Bowel Diseases
The invention provides a method for ameliorating gastrointestinal inflammation, particularly chronic gastrointestinal inflammation such as inflammatory bowel disease (IBD), in a subject. In one embodiment, the method comprises administering an immunomodulatory nucleic acid to a subject suffering from or susceptible to gastrointestinal inflammation.
Owner:RGT UNIV OF CALIFORNIA +1
Methods of treating gastrointestinal inflammation
InactiveUS20070004654A1Improve the level ofBiocidePeptide/protein ingredientsGastrointestinal inflammationCrohn's disease
The present invention provides methods of treating gastrointestinal inflammation, methods of treating inflammatory bowel disease, methods of treating Crohn's Disease, and methods of treating ulcerative colitis in an individual. The methods generally involve administering an effective amount of an agent that increases the level of a Type I interferon and / or that activates a Type I interferon signaling pathway in the individual.
Owner:RGT UNIV OF CALIFORNIA
Method of using abscisic acid to treat and prevent diseases and disorders
ActiveUS20100216883A1Increasing CTLA- expressionAlter activityBiocideDigestive systemGastrointestinal inflammationAbscisic acid
Methods and compositions for treating inflammatory bowel disease, gastrointestinal inflammation and maintaining normal gut health are described. These methods of the invention involve the administration of abscisic acid in amounts sufficient to alter the expression or activity of PPAR gamma in a cell. Also described are methods for suppressing the expression of cellular adhesion molecules in the gut and methods for increasing CTLA-4 expression on CD4+ T cells through administration of abscisic acid.
Owner:VIRGINIA TECH INTPROP INC
Method and composition for treatment of inflammatory conditions
Methods of treating inflammation of the gastrointestinal tract and / or systemic or local inflammation by administering a steroid anti-inflammatory or a non-steroid anti-inflammatory drug in conjunction with polyunsaturated fatty acids or their derivatives and optionally also a pharmacologically active antioxidant and compositions for practicing these methods are described.
Owner:GUIVARCH POL HENRI +1
Orally administered corticosteroid compositions
ActiveUS8771729B2Antibacterial agentsPowder deliveryGastrointestinal inflammationGastrointestinal tract
The present invention is directed to orally administered corticosteroid compositions. The present invention also provides a method for treating a condition associated with inflammation of the gastrointestinal tract in an individual. The method comprises administering to an individual in need thereof a pharmaceutical composition of the present invention.
Owner:ELLODI PHARM LP
Methods of treating eosinophilic esophagitis
ActiveUS20180133145A1Raise countNo worseningOrganic active ingredientsAntipyreticGastrointestinal inflammationUpper gastrointestinal
The present disclosure provides methods of treating inflammation of the upper gastrointestinal tract, especially the esophagus, by administering an oral corticosteroid. In some cases, the methods include treating eosinophilic esophagitis (EoE) by administering an oral corticosteroid in an induction phase and a maintenance phase to improve peak eosinophilic counts and symptoms. In embodiments, the methods include treating EoE by administering the oral corticosteroid at nighttime and / or while the patient is lying down.
Owner:ELLODI PHARM LP
Method for differentiating irritable bowel syndrome from inflammatory bowel disease (IBD) and for monitoring persons with IBD using total endogenous lactoferrin as a marker
InactiveUS7192724B2Decreasing and eliminating gastrointestinal inflammationLower Level RequirementsDisease diagnosisBiological testingEtiologyGastrointestinal inflammation
A method for aiding in differentiating irritable bowel syndrome from inflammatory bowel disease by determining the level of total endogenous human lactoferrin in clinical specimens, such as feces, mucus and bile, wherein an elevated level of lactoferrin substantially precludes diagnoses of IBS and other noninflammatory etiologies, and a kit usable in such method are provided. Further provided is a method for quantitating the level of total endogenous human lactoferrin in clinical specimens, such as feces, mucus and bile, to monitor gastrointestinal inflammation in persons having inflammatory bowel disease.
Owner:TECH LAB
Methods of treating gastrointestinal inflammation
The present invention provides methods of treating gastrointestinal inflammation, methods of treating inflammatory bowel disease, methods of treating Crohn's Disease, and methods of treating ulcerative colitis in an individual. The methods generally involve administering an effective amount of an agent that increases the level of a Type I interferon and / or that activates a Type I interferon signaling pathway in the individual.
Owner:RGT UNIV OF CALIFORNIA
Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis
ActiveUS20160206627A1High blend uniformity/homogeneityOrganic active ingredientsAntipyreticGastrointestinal inflammationOral medication
The present invention is directed to orally administered compositions of topically acting corticosteroids for the treatment of inflammation of the gastrointestinal tracts such as eosinophilic esophagitis. The present invention also provides a method for treating conditions associated with inflammation of the gastrointestinal tract in an individual. The method comprises administering to an individual in need thereof a phermaceutical compossition of the present invention as orally disintegrating tablets comprising a topically active corticosteroid adsorbed onto a pharmaceutically acceptable carrier such as silicified microcrystalline cellulose.
Owner:ADARE PHARMA US LP
Methods of treating eosinophilic esophagitis
ActiveUS10105315B2Raise countNo worseningOrganic active ingredientsAntipyreticGastrointestinal inflammationUpper gastrointestinal
The present disclosure provides methods of treating inflammation of the upper gastrointestinal tract, especially the esophagus, by administering an oral corticosteroid. In some cases, the methods include treating eosinophilic esophagitis (EoE) by administering an oral corticosteroid in an induction phase and a maintenance phase to improve peak eosinophilic counts and symptoms. In embodiments, the methods include treating EoE by administering the oral corticosteroid at nighttime and / or while the patient is lying down.
Owner:ELLODI PHARM LP
Selection and use of lactic acid bacteria for reducing inflammation caused by Helicobacter
ActiveUS7105336B2Reducing gastrointestinal inflammationAntibacterial agentsBiocideGastrointestinal inflammationHelicobacter
Strains of Lactobacillus which have been selected for their capability of reducing gastrointestinal inflammation, such as that due to Helicobacter pylori, and products derived from these strains, including agents for treatment or prophylaxis of inflammation associated with Helicobacter pylori for administration to humans and include conditioned media in which the selected strains have grown and protein-containing extracts of the conditioned media.
Owner:BIOGAIA AB
Use of Lactobacillus salivarius
InactiveUS20030166257A1Control damageReduce rateAntipyreticAnalgesicsLactobacillus salivariusHuman gastrointestinal tract
Lactobacillus salivarius is useful in the prophylaxis or treatment of undesirable inflammatory activity, especially gastrointestinal inflammatory activity such as inflammatory bowel disease or irritable bowel syndrome. The inflammatory activity may also be due to cancer. The Lactobacillus salivarius is of human origin isolated from resected and washed human gastrointestinal tract. One such strain is UCC 118 described in WO-A-9835014.
Owner:ENTERPRISE IRELAND +1
Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis
A method of treatment of inflamed, pre-cancerous or cancerous tissue or polyps in a mammalian subject is disclosed. The treatment involves administration of a composition of at least one peptide agonist of a guanylate cyclase receptor and / or other small molecules that enhance intracellular production of cGMP. The at least one peptide agonist of a guanylate cyclase receptor may be administered either alone or in combination with an inhibitor of cGMP-dependent phosphodiesterase. The inhibitor may be a small molecule, peptide, protein or other compound that inhibits the degradation of cGMP. Without requiring a particular mechanism of action, this treatment may restore a healthy balance between proliferation and apoptosis in the subject's population of epithelial cells, and also suppress carcinogenesis. Thus, the method may be used to treat, inter alia, inflammation, including gastrointestinal inflammatory disorders, general organ inflammation and asthma, and carcinogenesis of the lung, gastrointestinal tract, bladder, testis, prostate and pancreas, or polyps.
Owner:SYNERGY PHARMA
Kit for quantitatively detecting vibrio parahaemolyticus in food and clinic sample
ActiveCN101709331AHigh sensitivityEffective monitoringMicrobiological testing/measurementMicroorganism based processesDiseaseForward primer
The invention discloses a kit for quantitatively detecting vibrio parahaemolyticus in food and clinic sample. The kit comprises respectively packaged DNA extracting solution, PCR amplification reaction liquid, negative standard substance, positive reference material, quantitative standard substance and a plurality of sealed reagent bottles or test tubes. The invention is characterized in that the PCR amplification reaction liquid contains forward primer VP-F, reverse primer VP-R, oligonucleotide probe VP-P, heat-resistant DNA polymerase and deoxyribonucleoside triphosphate for target polynucleotide amplification. The vibrio parahaemolyticus pathogen in food samples and samples of puke, blood and dejection of patient with clinic gastrointestinal inflammation or visceral hemorrhage can be detected, thereby being capable of providing reliable experimental evidences for sensitively and quickly diagnosing vibrio parahaemolyticus pollution and infection and repetitive infection of vibrio parahaemolyticus at an early time; and simultaneously, the amount can be accurately fixed, thereby being capable of effectively monitoring clinic drug administration.
Owner:XIAN TIANLONG SCI & TECH
Method for monitoring gastrointestinal inflammation in persons with inflammatory bowel disease(IBD)
InactiveUS7560240B2Easy to useRead intuitivelyBiocideOrganic active ingredientsEtiologyGastrointestinal inflammation
Owner:TECH LAB
Compositions and methods for the treatment of gastrointestinal conditions
InactiveUS20080118441A1Few and no side effectSuitable for useBiocideAerosol deliveryIntestinal structureDiverticulitis
Gastrointestinal conditions, such as gastroesophageal reflux disease, heartburn, acid indigestion, constipation, irritable bowel syndrome, stomach and intestinal ulcers, gastrointestinal tract inflammation, thrush, diverticulitis, ulcerative colitis, Crohn's disease, diarrhea and cancers of the esophagus, pancreas, stomach, intestines and colon, may be treated or prevented by administration of compositions containing a therapeutically effective amount of a fatty acid and a therapeutically effective amount of mucilaginous fiber. Fatty acids suitable for use in the compositions include omega-3 fatty acids, omega-6 fatty acids and / or omega-9 fatty acids.
Owner:WASHINGTON JOSEPH A
Oral gram(+) bacteria and glutamine composition for prevention and/or treatment of gastro-intestinal dysfunctions including inflammation in the gastro-intestinal tract, neonatal necrotizing enterocolitis (nec) and bacterial sepsis
A composition and method for treating and preventing gastro-intestinal injury are disclosed. The composition includes a combination of Gram (+) bacteria, in particular Lactobacillus and / or Bifidobacteria, and glutamine. The method involves orally or naso-gastrically administering a composition containing Gram (+) bacteria, in particular Lactobacillus, and glutamine. The composition, which blocks translocation of bacterial agents such as Gram (-) bacteria, other infectious agents, toxins, chemicals and injurious substances, may be used in the prevention and treatment of symptoms and / or disease that result from translocation of Gram (-) bacteria, including inflammation in the gastro-intestinal tract, Neonatal Necrotizing Enterocolitis (NEC) and bacterial sepsis.
Owner:PANIGRAHI PINAKI
Compositions for the treatment of gastrointestinal inflammation
Owner:VIROPHARMA HLDG
Treatment of gastrointestinal dysfunction and related stress with an enantiomerically-pure (S)-2,3-benzodiazepine
InactiveUS20050288277A1Useful in treatmentInhibition formationBiocideAnimal repellantsBenzodiazepineGastrointestinal inflammation
The present invention relates to methods of treatment for symptoms of gastrointestinal dysfunction and related stress which are frequently associated with, for example, irritable bowel syndrome. The symptoms include altered bowel motility, gastrointestinal inflammation, visceral hypersensitivity, or gastric ulcers.
Owner:VELA ACQUISITION
Pyrazolo (3, 4-b) pyridine derivatives as phosphodiesterase inhibitors
The present invention relates to phosphodiesterase (PDE) type 4, phosphodiesterase (PDE) type 7 and dual PDE type 4 / PDE type 7 inhibitors. Compounds disclosed herein having the structure of Formula 1: can be useful in the treatment, prevention, inhibition or suppression of CNS diseases, for example, multiple sclerosis; various pathological conditions such as diseases affecting the immune system, including AIDS, rejection of transplant, auto-immune disorders such as T-cell related diseases, for example, rheumatoid arthritis; inflammatory diseases such as respiratory inflammation diseases including chronic obstructive pulmonary disease (COPD), asthma, bronchitis, allergic rhinitis, adult respiratory distress syndrome (ARDS) and other inflammatory diseases including but not limited to psoriasis, shock, atopic dermatitis, eosinophilic granuloma, allergic conjunctivitis, osteoarthritis; gastrointestinal inflammation diseases such as Crohn's disease, colitis, pancreatitis as well as different types of cancers including leukaemia; especially in humans. Processes for the preparation of disclosed compounds, pharmaceutical compositions containing the disclosed compounds and their use as PDE type 4, PDE type 7 and dual PDE type 4 / PDE type 7 inhibitors are provided.
Owner:SUN PHARMA INDS
Disodium sulfodehydroabietate (DSDA) and composition and application thereof
ActiveCN101590031AGood curative effectQuick resultsOrganic active ingredientsDigestive systemDiseaseIntestinal structure
The invention discloses disodium sulfodehydroabietate (DSDA) and a composition, a preparation method and application thereof in medicaments for preventing hyperacid peptic ulcer and gastrointestinal inflammation. A patent application disclosed by CN00818150.0 is of the opinion that monosodium sulfodehydroabietate is superior to disodium salt, but does not further disclose test conditions and data conclusion; moreover, the pharmacological action and clinical application of the disodium salt deserve further research. The invention compares the in-vitro acid making effects of monosodium salt and the disodium salt, the dissolution of the monosodium salt and the disodium salt in artificial gastric juice and intestinal juice as well as the clinical efficacies in treating gastric ulcer, acute gastritis and acute attack of chronic gastritis. Results show that DSDA has the advantages that DSDA has stronger acid-making capability during treating the gastric ulcer, acute gastritis and acute attack of chronic gastritis and faster dissolution speed in stomach and intestine; and medicaments prepared from the DSDA have better curative effect and quick response.
Owner:ZHEJIANG ASEN PHARMA
Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis
ActiveUS10471071B2High blend uniformity/homogeneityOrganic active ingredientsAntipyreticGastrointestinal inflammationOrally disintegrating tablet
The present invention is directed to orally administered compositions of topically acting corticosteroids for the treatment of inflammation of the gastrointestinal tracts such as eosinophilic esophagitis. The present invention also provides a method for treating conditions associated with inflammation of the gastrointestinal tract in an individual. The method comprises administering to an individual in need thereof a pharmaceutical composition of the present invention as orally disintegrating tablets comprising a topically active corticosteroid adsorbed onto a pharmaceutically acceptable carrier such as silicified microcrystalline cellulose.
Owner:ADARE PHARMA US LP
Salts of 4- or 5-aminosalicylic acid
InactiveUS7326809B2Reduce inflammationPromote infiltrationBiocideOrganic chemistryGastrointestinal inflammationArginine
The present invention provides L-arginine salts of 4- or 5-aminosalicylic acid, and a pharmaceutical composition containing these L-arginine salts of 4- or 5-aminosalicylic acid as active ingredients, useful for the treatment of an inflammatory condition of the GI tract such as inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS).
Owner:ANTIBE HLDG
Treatment of gastrointestinal dysfunction and related stress with an enantiomerically-pure (S) 2,3-benzodiazepine
The present invention relates to methods of treatment for symptoms of gastrointestinal dysfunction and related stress that are frequently associated with, for example, irritable bowel syndrome. The symptoms include altered bowel motility, gastrointestinal inflammation, visceral hypersensitivity, or gastric ulcers.
Owner:VELA ACQUISITION
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com